ERBB3 and breast cancer: The SOLTI TOT-HER3 (NCT0461528) study evaluated HER3-DXd in treatment-naïve patients with HR+/HER2− BC and reported meaningful clinical response following a single HER3-DXd dose (6.4 mg/kg) [125,126].